Roivant Sciences reports $4.3 billion in cash reserves and higher R&D spending for fiscal Q4 ended March 31, 2026.
Guggenheim increased its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $36 from $30, maintaining a Buy rating after the company’s fiscal Q4 earnings and pipeline updates. Citi also raised its target to $42 from $35, citing potential share upside tied to 2026 data catalysts.
Roivant reported $4.3 billion in consolidated cash, cash equivalents, and marketable securities as of March 31, 2026. Research and development expenses rose to $198.9 million for the quarter, up $53.7 million from the same period in 2025.
The company focuses on developing treatments for psoriasis, thyroid eye disease, and atopic dermatitis, with key products including Vtama and Batoclimab.